MXPA06013079A - Identificacion y caracterizacion de un subconjunto de glioblastomas sensibles al tratamiento con imatinib. - Google Patents

Identificacion y caracterizacion de un subconjunto de glioblastomas sensibles al tratamiento con imatinib.

Info

Publication number
MXPA06013079A
MXPA06013079A MXPA06013079A MXPA06013079A MXPA06013079A MX PA06013079 A MXPA06013079 A MX PA06013079A MX PA06013079 A MXPA06013079 A MX PA06013079A MX PA06013079 A MXPA06013079 A MX PA06013079A MX PA06013079 A MXPA06013079 A MX PA06013079A
Authority
MX
Mexico
Prior art keywords
mammal
expression
growth factor
phosphorylation
platelet
Prior art date
Application number
MXPA06013079A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Hagerstrand
Goran Hessselager
Arne Ostman
Monica Nister
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0410883A external-priority patent/GB0410883D0/en
Priority claimed from GB0425257A external-priority patent/GB0425257D0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of MXPA06013079A publication Critical patent/MXPA06013079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MXPA06013079A 2004-05-14 2005-05-13 Identificacion y caracterizacion de un subconjunto de glioblastomas sensibles al tratamiento con imatinib. MXPA06013079A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0410883A GB0410883D0 (en) 2004-05-14 2004-05-14 Organic compounds
GB0425257A GB0425257D0 (en) 2004-11-16 2004-11-16 Organic compounds
PCT/EP2005/005269 WO2005113801A2 (en) 2004-05-14 2005-05-13 Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib

Publications (1)

Publication Number Publication Date
MXPA06013079A true MXPA06013079A (es) 2007-10-08

Family

ID=35295424

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013079A MXPA06013079A (es) 2004-05-14 2005-05-13 Identificacion y caracterizacion de un subconjunto de glioblastomas sensibles al tratamiento con imatinib.

Country Status (9)

Country Link
US (1) US20080199855A1 (enExample)
EP (1) EP1756306A2 (enExample)
JP (1) JP2007536920A (enExample)
AU (1) AU2005245572B9 (enExample)
BR (1) BRPI0511088A (enExample)
CA (1) CA2564654A1 (enExample)
MX (1) MXPA06013079A (enExample)
RU (1) RU2006144122A (enExample)
WO (1) WO2005113801A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132336A1 (en) * 2007-03-02 2009-12-16 Board of Regents, The University of Texas System Multigene assay to predict outcome in an individual with glioblastoma
US20110064747A1 (en) * 2009-08-25 2011-03-17 Rangaprasad Sarangarajan Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
SG11201504023SA (en) 2012-12-03 2015-06-29 Almac Diagnostics Ltd Molecular diagnostic test for cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829154B1 (fr) * 2001-09-05 2003-10-17 Assist Publ Hopitaux De Paris Nouveau procede de detection d'une mutation en phase de lecture dans une sequence codante et appareil pour sa mise en oeuvre
JP2005522221A (ja) * 2002-04-17 2005-07-28 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤に対する患者応答性の予測方法
JP4035600B2 (ja) * 2002-05-22 2008-01-23 国立大学法人 東京大学 イマチニブに対する感受性の判定方法

Also Published As

Publication number Publication date
WO2005113801A3 (en) 2006-02-23
WO2005113801A2 (en) 2005-12-01
JP2007536920A (ja) 2007-12-20
US20080199855A1 (en) 2008-08-21
BRPI0511088A (pt) 2007-12-26
RU2006144122A (ru) 2008-06-20
AU2005245572A1 (en) 2005-12-01
AU2005245572B2 (en) 2008-12-04
EP1756306A2 (en) 2007-02-28
CA2564654A1 (en) 2005-12-01
AU2005245572B9 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
US20240124937A1 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
JP2009523410A (ja) 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
Kimani et al. Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase
US10017822B2 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma
JP2019503176A (ja) 処置に対する応答を予測するための方法
Ou et al. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors
EP1611890B1 (en) Methods for assessing and treating cancer
JP6549147B2 (ja) Ｎｒａｓ変異癌の処置における使用のためのｅｇｆｒ阻害剤とｍｅｋ阻害剤の組合せ
MXPA06013079A (es) Identificacion y caracterizacion de un subconjunto de glioblastomas sensibles al tratamiento con imatinib.
Booth et al. Gene expression profiles at different stages of collagen-induced arthritis
AU2004202980B2 (en) Methods for assessing and treating leukemia
CN101586153A (zh) 预测表皮生长因子受体抑制剂疗效的试剂盒
CN101586154A (zh) 预测表皮生长因子受体抑制剂疗效的试剂盒
CN101586151A (zh) 预测表皮生长因子受体抑制剂疗效的试剂盒
CN1997755A (zh) 对伊马替尼治疗敏感的胶质母细胞瘤亚群的鉴定和表征
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
Liu et al. Knockdown of PREX2a inhibits the malignant phenotype of glioma cells Retraction in/10.3892/mmr. 2021.12184
US20250179579A1 (en) Method of detecting urothelial or bladder cancer in a liquid sample
KR20070031902A (ko) 이매티닙을 사용하는 치료에 대하여 감수성인아교모세포종의 서브세트의 확인 및 특성화
CN101586152A (zh) 预测表皮生长因子受体抑制剂疗效的试剂盒
JP2011505807A (ja) キナゾリノン化合物による治療をモニタリングするためのバイオマーカー
Shokeen Submitted by
Kazemier et al. The expression of 70 apoptosis genes in relation to lineage, genetic
US20030129616A1 (en) Use of a mutation in the gene for the beta3-subunit of human g-protein
JP2013063952A (ja) エザチオスタットによって骨髄異形成症候群を治療する方法

Legal Events

Date Code Title Description
FA Abandonment or withdrawal